Traversa Founder Says Multi-Targeting Approach Key to RNAi-Based Cancer Drugs
May 27, 2010
Traversa Founder Says Multi-Targeting Approach Key to RNAi-Based Cancer Drugs
Last week, Traversa Therapeutics founder Steve Dowdy presented data at the annual meeting of the American Society of Gene and Cell Therapy in Washington, DC, describing his lab's development of an siRNA cocktail against glioblastoma that incorporates a proprietary delivery technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - RNAi Drug Delivery Startup Solstice Closes $18M Series Financing Round
January 10, 2013 / Gene Silencing News - Bankrupt Traversa Settles IP Dispute as Alnylam, Isis Claim Delays in Tekmira Suit
September 6, 2012 / Gene Silencing News - Traversa Responds to Former Execs Bid to Block Sale of IP in Bankruptcy Proceedings
August 23, 2012 / Gene Silencing News - Former Traversa Exec Moves to Block Sale of Certain IP in Bankruptcy Proceedings
August 16, 2012 / Gene Silencing News